Benefit-risk analysis for the clinician: 'primum non nocere' revisited-the case for antipsychotics in the treatment of behavioural disturbances in dementia

International Journal of Geriatric Psychiatry

Volumn 25, Issue 5, 2010, Pages 437-440

  Naarding, P ^a   Van Grevenstein, M ^a   Beekman, A T F ^b  

^a GGNet Mental Health   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antipsychotics; Behaviour; Decision analysis; Dementia

Indexed keywords

NEUROLEPTIC AGENT;

AGING; ANALYTIC METHOD; BEHAVIOR DISORDER; DEMENTIA; HUMAN; MEDICAL DECISION MAKING; MOTOR DYSFUNCTION; OUTCOME ASSESSMENT; PARKINSONISM; REVIEW; RISK BENEFIT ANALYSIS; SEDATION; STROKE;

AGED; ANTIPSYCHOTIC AGENTS; DECISION MAKING; DECISION SUPPORT TECHNIQUES; DEMENTIA; HIPPOCRATIC OATH; HUMANS; MENTAL DISORDERS; RISK ASSESSMENT;

EID: 77950840270     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.2357     Document Type: Review

References (8)

1. Ballard CG, Waite J, Birks J. 2006. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 25(1): CD003476.
2. Ballard C, Hanney ML, Theodoulou M, et al. 2009. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 8: 151-157.
3. Conradi P. 2008. Antipsychotics and, stroke risk: madness of modern medicine [Letter]. BMJ 337: 647.
4. Douglas IJ, Smeeth L. 2008. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ 337: a1227.
5. Holden WL. 2003. Benefit-risk Analysis: a brief review and proposed quantitative approaches. Drug Saf 26: 853-862.
6. Kapur N. 2000. Evaluating risks. Adv Psychiatr Treatment 6: 399-406.
7. Schneider LS, Tariot PN, Dagerman KS, et al. 2006. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. NEJM 355: 1525-1538. (Pubitemid 44547805)
8. Sultzer DL, Davis SM, Tariot PN, et al. 2008. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's Disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 165: 844-854.